Drug approval highlights for 2003

Gary Laustsen, Lynn Wimett

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

In the past 12 months, the FDA has approved important new pharmaceutical drugs and devices of particular interest to primary health care providers. The drugs include: Oxytrol (for urinary incontinence), Valtrex (for reducing the risk of heterosexual transmission of genital herpes), Femring (for vaginal delivery of hormone therapy), Uroxatral (for benign prostatic hypertrophy), Levitra (for erectile dysfunction), Flumist (for preventing influenza), Xolair (for asthma), Raptiva (for psoriasis), Cubicin (for skin infections), Crestor (for hypercholesterolemia), and Coreg (for severe heart failure).

Original languageEnglish (US)
Pages (from-to)8-21
Number of pages14
JournalNurse Practitioner
Volume29
Issue number2
DOIs
StatePublished - Feb 2004

ASJC Scopus subject areas

  • Nursing(all)

Fingerprint Dive into the research topics of 'Drug approval highlights for 2003'. Together they form a unique fingerprint.

  • Cite this